Diagnostic und Therapeutic Value of Cell-free Circulating DNA as a Non-invasive Biomarker in Patients with Prostate Cancer

2014 ◽  
Vol 9 (4) ◽  
pp. 258-264 ◽  
Author(s):  
Stefan Latz ◽  
Stefan C. Muller ◽  
Jorg Ellinger
Keyword(s):  
Prostate Cancer ◽  
Circulating Dna ◽  
Non Invasive ◽  
Therapeutic Value ◽  
Free Circulating Dna

scholarly journals Evaluation of Plasma Cell‐Free Circulating DNA Integrity in Patients with Prostate Cancer in Jamaica

2018 ◽  
Vol 32 (S1) ◽  
Author(s):  
Andrew Condappa ◽  
William Aiken ◽  
Wayne McLaughlin ◽  
Donovan McGrowder ◽  
Maxine Gossell‐Williams
Keyword(s):  
Prostate Cancer ◽  
Plasma Cell ◽  
Dna Integrity ◽  
Circulating Dna ◽  
Free Circulating Dna

scholarly journals Contrasting Circulating Tumor Cells and Free Circulating DNA Responses in Men Treated for Prostate Cancer after Primary Versus Salvage Radiotherapy

2020 ◽  
pp. 1-9
Author(s):  
Radka Stoyanova ◽  
Adrian L. Breto ◽  
Adrian Ishkanian ◽  
Alan Dal Pra ◽  
Alan Pollack ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Specific Antigen ◽  
Reciprocal Relationship ◽  
Salvage Radiotherapy ◽  
Biochemical Response ◽  
Circulating Dna ◽  
Phase Ii Trials ◽  
Free Circulating Dna

Purpose: To investigate the relationships between circulating tumor cells (CTCs), free circulating DNA (fcDNA) and biochemical response in prostate cancer patients treated primarily versus salvage radiotherapy (RT). Methods and Materials: Blood was collected prospectively from patients, enrolled in two institutional Phase II trials for primary and salvage RT. Three blood samples were collected at: (i) prior to treatment [RT or androgen deprivation therapy (ADT)], (ii) last week of RT, and (iii) three months post-RT. CTCs were quantified in 31 samples from 12 primary patients and 30 samples from 12 salvage patients; fcDNA were analyzed in 11 primary (28 samples) and 5 (9 samples) salvage patients. CTCs were visualized by immunofluorescence after microfilter capture and fcDNA was quantified using real-time Polymerase chain reaction (PCR). CTCs and fcDNA were correlated with early biochemical response by subdividing patients into early favorable and unfavorable response at 3 months after RT. Results: For those treated primarily, there was a direct correlation with CTC counts and prostate specific antigen (PSA) pre-RT that changed to a reciprocal relationship 3 months post-RT. CTCs increased significantly (p=0.03) at 3 months after primary RT in the biochemical favorable patients, while no significant association was observed for fcDNA. Correspondingly, post-RT fcDNA levels were inversely related to CTC counts. In salvage patients, the number of CTCs was related to pre-RT PSA, but it was not correlated to RT response. In post-RT series, a significant direct correlation was observed between CTCs and PSA. Conclusion: Our preliminary studies suggest that RT affects CTC counts, which are thus associated with prostate cancer biochemical response. A larger cohort with longer follow-up will be needed to establish the association with more recognized treatment endpoints.

Cell-free circulating DNA as a promising marker of colorectal cancer detection and progression

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 11059-11059
Author(s):  
S. Pucciarelli ◽  
M. Enzo ◽  
M. Agostini ◽  
S. Pizzini ◽  
P. Del Bianco ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Healthy Subjects ◽  
P Value ◽  
Circulating Dna ◽  
Plasma Samples ◽  
Alu Repeats ◽  
Non Invasive ◽  
Total Dna ◽  
Free Circulating Dna ◽  
Normal Controls

11059 Background: Since the pathologic stage is the most powerful prognostic factor for colorectal cancer (CRC), there is a strong need of non-invasive methods for early detection. Cell-free circulating DNA (cfDNA) released from cancer cells varies in size. It has been suggested that cfDNA (ALU repeats of 115 bp, representative of total DNA; ALU repeats of 247 DNA, representative of tumor DNA) may be associated with presence of tumor. Aim of this study was then to investigate whether the cfDNA may have a role as marker of CRC detection and progression. Methods: cfDNA was extracted from plasma samples from 136 patients with primary CRC at different stages [median age 64 yrs; male/female 78/58; stages I-II, 61; stages III-IV, 75], and from 24 patients with adenomas [median age 67 yrs; male/female 17/7)] and from 55 clean-colon healthy subjects [median age 56 yrs; male/female 13/43). cfDNA was assessed by quantitative real-time PCR (qPCR) of ALU repeats with 2 sets of primers (115 and 247 bp) amplifying different lengths of DNA. The levels of cfDNA (ALU-115, ALU-247) of CRC patients (stages I-II and stages III-IV) were compared with those of healthy subjects and patients with adenoma. Results: The median concentrations of total cfDNA (ALU115) in the plasma samples from patients with stages III-IV and stages I-II CRC, adenoma and normal controls were 52,4, 11.9; 1.9, and 1.7 ng/ml, respectively (p<.0001). The corresponding figures for tumor-related cfDNA (ALU247) were 48.8, 4.7, 2.2, and 0.7 ng/ml, respectively. (p<.0001). With a cut-off of 4.86 ng/ml, total DNA (ALU115) showed a sensitivity of 78.52 (95% CI 70.6–85.1) and a specificity of 86.08 (95% CI 76.4–92.8) in distinguishing patients with CRC from non-CRC [AUC: 0.860 (95% CI 0.81–0,90), p-value=.0001]. With a cut-off of 3.04, cfDNA tumor-related (ALU247) showed a sensitivity of 77.94 (95% CI 70.0–84.6) and a specificity of 82.28 (95% CI 72.1–90.0) in distinguishing patients with CRC from non-CRC [AUC: 0.864 (95% CI 0.81–0,91), p-value=.0001]. Conclusions: Both ALU115 and ALU 247 fragments of circulating cfDNA seem promising non-invasive molecular markers of detection and progression of CRC. The findings of the current study require to be confirmed on larger cohorts of patients with CRC and colonic adenoma. No significant financial relationships to disclose.

Serum-free circulating DNA as a biomarker of prostate cancer diagnosis.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 4640-4640
Author(s):  
E. Gordian ◽  
K. Ramachandran ◽  
I. M. Reis ◽  
M. Manoharan ◽  
M. S. Soloway ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Diagnosis ◽  
Circulating Dna ◽  
Prostate Cancer Diagnosis ◽  
Serum Free ◽  
Free Circulating Dna

1736 SERUM FREE CIRCULATING DNA AS A BIOMARKER FOR PROSTATE CANCER DIAGNOSIS

2010 ◽  
Vol 183 (4S) ◽  
Author(s):  
Rakesh Singal ◽  
Edna Gordian ◽  
Kavitha Ramachandran ◽  
Devendar Katkoori ◽  
Isildinha Reis ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Diagnosis ◽  
Circulating Dna ◽  
Prostate Cancer Diagnosis ◽  
Serum Free ◽  
Free Circulating Dna

Characterization of cell-free circulating DNA in plasma in patients with prostate cancer

Tumor Biology ◽  
2012 ◽  
Vol 34 (2) ◽  
pp. 983-986 ◽  
Author(s):  
Pâmela Oliveira Delgado ◽  
Beatriz Costa A. Alves ◽  
Flávia de Sousa Gehrke ◽  
Renata Kelly Kuniyoshi ◽  
Marcelo Langer Wroclavski ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Circulating Dna ◽  
Free Circulating Dna

METHYLATION OF GSTP1, RARB AND RASSF1A IN FREE CIRCULATING DNA AND BUFFY COAT DNA IN PROSTATE CANCER PATIENTS AND CONTROLS

2008 ◽  
Vol 179 (4S) ◽  
pp. 461-461
Author(s):  
Rakesh Singal ◽  
Kavitha Ramachandran ◽  
Isildinha Reis ◽  
Merce Jorda ◽  
Murugesan Manoharan
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Buffy Coat ◽  
Circulating Dna ◽  
Free Circulating Dna

scholarly journals Exosomes as A Next-Generation Diagnostic and Therapeutic Tool in Prostate Cancer

2021 ◽  
Vol 22 (18) ◽  
pp. 10131
Author(s):  
Simita Gaglani ◽  
Edgar Gonzalez-Kozlova ◽  
Dara J. Lundon ◽  
Ashutosh K. Tewari ◽  
Navneet Dogra ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Liquid Biopsy ◽  
Specific Antigen ◽  
Unmet Need ◽  
Diagnostic Value ◽  
Advanced Technology ◽  
Detection Methods ◽  
Current Application ◽  
Non Invasive ◽  
Therapeutic Value

Extracellular vesicles (EVs) have brought great momentum to the non-invasive liquid biopsy procedure for the detection, characterization, and monitoring of cancer. Despite the common use of PSA (prostate-specific antigen) as a biomarker for prostate cancer, there is an unmet need for a more specific diagnostic tool to detect tumor progression and recurrence. Exosomes, which are EVs that are released from all cells, play a large role in physiology and pathology, including cancer. They are involved in intercellular communication, immune function, and they are present in every bodily fluid studied—making them an excellent window into how cells are operating. With liquid biopsy, EVs can be isolated and analyzed, enabling an insight into a potential therapeutic value, serving as a vehicle for drugs or nucleic acids that have anti-neoplastic effects. The current application of advanced technology also points to higher-sensitivity detection methods that are minimally invasive. In this review, we discuss the current understanding of the significance of exosomes in prostate cancer and the potential diagnostic value of these EVs in disease progression.

The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer

2011 ◽  
Vol 29 (2) ◽  
pp. 124-129 ◽  
Author(s):  
Jörg Ellinger ◽  
Stefan C. Müller ◽  
Thomas C. Stadler ◽  
Andreas Jung ◽  
Alexander von Ruecker ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Circulating Dna ◽  
Diagnosis And Prognosis ◽  
Free Circulating Dna
Sign in / Sign up

Export Citation Format

Share Document